Clinical Trials
10 trialsNCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT03781219 2023-05-31
A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation
Shanghai Kechow Pharma, Inc.
Phase 1 Unknown
NCT05233332 2023-05-31
mCRC
Shanghai Kechow Pharma, Inc.
Phase 2 Unknown
NCT05263453 2023-05-31
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
Shanghai Kechow Pharma, Inc.
Phase 2 Unknown
NCT02036086 2022-10-27
Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
Sunnybrook Health Sciences Centre
Phase 2 Unknown
NCT05019534 2022-05-19
Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer
West China Hospital
Phase 1 Unknown
NCT03239015 2022-03-04
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT03727763 2021-08-19
Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT02968303 2020-06-05
COWBOY
Radboud University Medical Center
Phase 2 Unknown
NCT02638428 2020-03-19
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Phase 2 Unknown